{"name":"Day One Biopharmaceuticals","slug":"day-one","ticker":"DAWN","exchange":"NASDAQ","domain":"dayonebio.com","description":"Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of ","hq":"Brisbane, CA","founded":0,"employees":"178","ceo":"Jeremy Bender","sector":"Pediatric Oncology","stockPrice":21.53,"stockChange":0,"stockChangePercent":0,"marketCap":"$2.2B","metrics":{"revenue":158182000,"revenueGrowth":83.9,"grossMargin":89.1,"rdSpend":148135000,"netIncome":-107322000,"cash":441112992,"dividendYield":0,"peRatio":-504.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"DAWN-011 patent cliff ($0.0B at risk)","drug":"DAWN-011","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"DAWN-032 patent cliff ($0.0B at risk)","drug":"DAWN-032","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"DAWN-011 Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL)","summary":"DAWN-011, a CD19-targeting antibody-drug conjugate, has received FDA Fast Track Designation for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).","drugName":"DAWN-011","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Day One Biopharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Day One Biopharmaceuticals reported its third quarter 2023 financial results, with a net loss of $23.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQT09YNzZkM0RkZndJRHlZZm81NzdZOE80SGNpdFZ5bUMxV3Qyd2hUVjQ5Ui1XWnNtVmlMMHp6LTZUVEhhUHZ0ZXFUdUlDMEZvcHJvRzZ6cjhyeXNWaGR5SXBDQ3EzdUxZQUJ4RFphQk0tcml1TDhVdHhvWWhDQXJ3TEFwMUlBME1xQ0dn?oc=5","date":"2026-03-09","type":"deal","source":"Finviz","summary":"DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - Finviz","headline":"DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOa1lNOWl0cXpGS0d1eUczVlhmcF9qcklsbmR4SUhjcFp5OXhkODRyNWF3N0lvNThIQXJEMDFMSmdwVW9CaExJYUdMai1LTE4zNTVseEFQSG9ZLVFpOTlPY2d3OWQ2NHNMTnVKa2tTSEZ4SDJqd19rUk9MeldmODNIWm1YdXdPMDFvNE1tS0VYWHR3WHNvcnFqSjZSMGxOMDUxZldXRHhQMkxLNmVjRGVMVnY2bGlnNWxIUnBR?oc=5","date":"2026-03-07","type":"deal","source":"International Business Times Australia","summary":"Day One Biopharmaceuticals (DAWN) Stock Surges 66% on Servier's $2.5 Billion Acquisition Deal - International Business Times Australia","headline":"Day One Biopharmaceuticals (DAWN) Stock Surges 66% on Servier's $2.5 Billion Acquisition Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQdUV2T0hqeVdfa0pWdUZIc2NOaWVXUDE1VGswcVF3RHVhN1RvWHY4bGVUMTAzcUxqS05zVWRXUUJhNnhuTk9sVWhOQi0yaHpVbVBTY0NJRHZLQUJrS3R3ckNIMXpSTzJSdkc4Q2txZjltaEswLUU1RERTNm5FbnlRTHpsRlpjREtKMERadU13bzFKQkU?oc=5","date":"2026-03-06","type":"pipeline","source":"Investor's Business Daily","summary":"Why A 'White Knight' Could Still Fight For Day One Bio - Investor's Business Daily","headline":"Why A 'White Knight' Could Still Fight For Day One Bio - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPQTh2Z3Z6SGN2a2xZQ1c5eEZtb3NycHJ1d0tpRU1Ic0dGdXdITkhhRldqZ3RaV3JtazlLcGdNMk1iUE1GbGgxVTMxTTl4SWxkT3A4eDV6NkxacklpaVhwOW51WnBDc3lMRnlVd0l6UEtidVhHRElUTDl1aTJST2ZpYg?oc=5","date":"2026-03-06","type":"deal","source":"Seeking Alpha","summary":"Day One Biopharma to be acquired by Servier for $2.5B - Seeking Alpha","headline":"Day One Biopharma to be acquired by Servier for $2.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNcGdTN2lIOWt1a0dsOU9Cc3ZjVnJyRGc2Z0xjYWY2dmRUV1lHLVVYX1RVa0xhZWNpQ3RxdmhYZlBTUnYwRHlPVFRRZTVZWF9WcUNhRzZLa0JRZzRDTTk5bnNFTUtmaDQtcGFZUGtNdFRDUkxSN3ZNakJMZ1dZTGVKNWR3MS1aVWJoODFtajE4ZDBCd3RyN0hOQUN4U2RDeW80OHlEZjFKUmtSeEwtb1RkYmlLbnNFcjJVX01ZcUo5TVBqYnFxVTlJaUVWemhCYmp2ZGJmYnVJWXZHU3Fic2E4TWIyQnRPc18zaXc4Z25VTEFMMXJQM09CUEdadFVDcVJSc1VlWW13?oc=5","date":"2026-03-06","type":"pipeline","source":"GlobeNewswire","summary":"Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio - GlobeNewswire","headline":"Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNVTFUNkJ0bG1kZURYd2trN2x2TW1WM0liWGhGVzZxU0lRT0JVb0NvcHRFNTc2WGhwcTkwanFHek10eGFIbWVUXzBfTzY2SHRqMUtialY2VkNMUHVNYUxVbVEzbmRUWlhyM0w0UGdJY0JmRW1lN19QQ1dQSUdhWFBTbWR2eHBPeG8?oc=5","date":"2026-03-06","type":"deal","source":"The Pharma Letter","summary":"Servier to acquire Day One Biopharma - The Pharma Letter","headline":"Servier to acquire Day One Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQZWxFdFBBSEhDcGl1ZVFOczNfSTNSSUJLOTV5VjltQ0Fna2NheFlfZTYtWnVyeTlJRjNqZ1luNzk1aHBFSkNFa0VPUzZfR05xWUJKOXB1aWN3bUpyLUI1cTJCWW52cy1aX1Jxc3V0X3NRSTg4cWJMMzJET0RmRXJKbDBVTlJUX2VnLW1XUTFvSWdIb3dTc09XZnBJcXFiV3hiMWlFUlBNSlFIS0xoRDNJ?oc=5","date":"2026-03-06","type":"pipeline","source":"TradingView","summary":"Is there any upside left in DAWN stock as it soars 65%? - TradingView","headline":"Is there any upside left in DAWN stock as it soars 65%?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxONl90dFRqLU1VNzVMbFVJUzc4RUN1SDdBaTJrSDhwWTZBZmhwd2pMcHY2Z2s0WHNfdm1HR2lJRHlvTnlIMWJYNWZBWTlpMFFRRk5OeXlUbjBEZHkya3gxNlYyQXFKenBfd3BxOEl5aTNDdW9fLVhIWmRIYXF4T1QybWpnWTJpUTF6ZmN1SWROSXhIcHZCYlpISkw3M2t6SFk?oc=5","date":"2026-03-06","type":"deal","source":"Blockonomi","summary":"Day One Biopharmaceuticals (DAWN) Stock Soars 66% on Servier Buyout Agreement - Blockonomi","headline":"Day One Biopharmaceuticals (DAWN) Stock Soars 66% on Servier Buyout Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE51UGM3eng2RXVQRVJ1UGZheDFITHRmajZpNU0wWGgwZWRFeHVuTWFaaUVvMTRPc01STHo3bVBnTG9qMW04WUlGU2p1TXhVTmc?oc=5","date":"2026-03-06","type":"deal","source":"MEXC","summary":"Day One Biopharmaceuticals (DAWN) Stock Jumps 66% After Servier Acquisition Deal - MEXC","headline":"Day One Biopharmaceuticals (DAWN) Stock Jumps 66% After Servier Acquisition Deal","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-26","type":"earnings","source":"simplywall.st","summary":"Day One Biopharmaceuticals (DAWN) Touts Narrower Q4 Loss Challenging Bearish Profitability Narratives - simplywall.st","headline":"Day One Biopharmaceuticals (DAWN) Touts Narrower Q4 Loss Challenging Bearish Profitability Narratives","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNSmE0S0FHUTFRNGxwa0MxU0l0RnZkWDgtRWVvblUydC1Ka2w2X0V4ZDl1aEh4Mi1JZ19OX3ZhelFuSEMzaW5OeE1nYWV6TTlrNkVNRWhib0s2Wno2eG1GUXAtekZHRm8ySmhMaWxieEJlS3ZGelZsbFAzVXdyR19TXy04ZHpNLTVhVFpFNVBfRHMzcl9sOGNVbS1td3pBV014SVJaelAyRDBRTGVVcWoxWHNIUEV3Tkh0bzJUZlJtLWpGYzdSOGZsSG02VFpzeDNBb2pzWmhkREpMb0ZYNHpia1ZyUXlOQ1ktMnFIMVpOYm4tZ9IB9wFBVV95cUxOR2NzUWpwZTFXc3duOTJZWUhwV2laM1kyYXk1Xzk5NndRVWpjRGVHNVVBV0V0WUtNQWlhNW8zR2dwTXNrc3BnUmtmdDdTUzhPdFhHVW1aakhKcHpYWVhwU2FTcVU4a1ZxYVhKVGVYUU12RERMendWcHRJOThSU2VzTlc2bEpWcWZITnlGVVJMUGFuYWZCTkxZTDlxbjRhRTR2TVA3bHY5TlRscjZvNld6aTV0c1NJM3NkaXlSSGhIeUFNZGhFY3lMLXVralUyWE1mZWR0VjBkUzA4dGViYVpoeFA5UVB3UVQyNnlmeGk2eU9lTzY1Rkh3?oc=5","date":"2026-01-21","type":"pipeline","source":"simplywall.st","summary":"Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking - simplywall.st","headline":"Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking","sentiment":"neutral"}],"patents":[{"drugName":"DAWN-032","drugSlug":"small-molecule-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0},{"drugName":"DAWN-011","drugSlug":"cd19-targeting-antibody-drug-conjugate","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Novartis","Amgen"],"therapeuticFocus":["Pediatric Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":158182000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":158182000,"period":"2025-12-31"},{"value":131161000,"period":"2024-12-31"},{"value":131161000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2023-12-31"}],"grossProfit":140972000,"grossProfitHistory":[{"period":"2025-12-31","value":140972000},{"period":"2024-12-31","value":125882000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"rdSpend":148135000,"rdSpendHistory":[{"period":"2025-12-31","value":148135000},{"period":"2024-12-31","value":227702000},{"period":"2023-12-31","value":130521000},{"period":"2022-12-31","value":85618000}],"sgaSpend":120587000,"operatingIncome":-127750000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-127750000},{"period":"2024-12-31","value":-217270000},{"period":"2023-12-31","value":-206064000},{"period":"2022-12-31","value":-146909000}],"netIncome":-107322000,"netIncomeHistory":[{"period":"2025-12-31","value":-107322000},{"period":"2024-12-31","value":-95496000},{"period":"2023-12-31","value":-188917000},{"period":"2022-12-31","value":-142181000}],"eps":-1.02,"epsHistory":[{"period":"2024-12-31","value":-1.02},{"period":"2023-12-31","value":-2.37},{"period":"2022-12-31","value":-2.17},{"period":"2021-12-31","value":-4.62}],"cash":197078000,"cashHistory":[{"period":"2025-12-31","value":197078000},{"period":"2024-12-31","value":124968000},{"period":"2023-12-31","value":230784000},{"period":"2022-12-31","value":85262000}],"totalAssets":507827000,"totalLiabilities":66665000,"totalDebt":2793000,"equity":441162000,"operatingCashflow":-103757000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-103757000},{"period":"2024-12-31","value":-78113000},{"period":"2023-12-31","value":-146853000},{"period":"2022-12-31","value":-109874000}],"capex":-3820000,"capexHistory":[{"period":"2025-12-31","value":-3820000},{"period":"2024-12-31","value":-74269000},{"period":"2023-12-31","value":-3224000},{"period":"2022-12-31","value":-26000}],"freeCashflow":-107577000,"dividendsPaid":null,"buybacks":null,"employees":178,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":34147000,"ebit":-27458000,"ebitda":-26464000,"period":"2025-12-31","revenue":53718000,"epsBasic":null,"netIncome":-21278000,"rdExpense":40948000,"epsDiluted":null,"grossProfit":47637000,"operatingIncome":-27458000},{"sga":28147000,"ebit":-24251000,"ebitda":-23317000,"period":"2025-09-30","revenue":39795000,"epsBasic":-0.19,"netIncome":-19726000,"rdExpense":31419000,"epsDiluted":-0.19,"grossProfit":35315000,"operatingIncome":-24251000},{"sga":28968000,"ebit":-34974000,"ebitda":-34010000,"period":"2025-06-30","revenue":33908000,"epsBasic":-0.29,"netIncome":-30322000,"rdExpense":36149000,"epsDiluted":-0.29,"grossProfit":30143000,"operatingIncome":-34974000},{"sga":29325000,"ebit":-41067000,"ebitda":-40173000,"period":"2025-03-31","revenue":30761000,"epsBasic":-0.35,"netIncome":-35996000,"rdExpense":39619000,"epsDiluted":-0.35,"grossProfit":27877000,"operatingIncome":-41067000},{"sga":29735000,"ebit":-65332000,"ebitda":-64573000,"period":"2024-12-31","revenue":29208000,"epsBasic":null,"netIncome":-65714000,"rdExpense":61823000,"epsDiluted":null,"grossProfit":26226000,"operatingIncome":-65332000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":0.38,"netIncome":null,"rdExpense":null,"epsDiluted":0.38,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":21.53,"previousClose":0,"fiftyTwoWeekHigh":21.53,"fiftyTwoWeekLow":5.63,"fiftyTwoWeekRange":"","fiftyDayAverage":18.63,"twoHundredDayAverage":10.96,"beta":-1.75,"enterpriseValue":1785679232,"forwardPE":-504.1,"priceToBook":5.03,"priceToSales":14.06,"enterpriseToRevenue":11.29,"enterpriseToEbitda":-14.37,"pegRatio":0,"ebitda":-124274000,"ebitdaMargin":-78.6,"freeCashflow":-61958752,"operatingCashflow":-103757000,"totalDebt":2793000,"debtToEquity":0.6,"currentRatio":8.02,"returnOnAssets":-14.6,"returnOnEquity":-22.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":6,"targetMeanPrice":21.5,"targetHighPrice":21.5,"targetLowPrice":21.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":16.8,"institutionHeldPercent":83.5,"sharesOutstanding":103334169,"floatShares":71347715,"sharesShort":6579076,"shortRatio":2.79,"shortPercentOfFloat":6.4,"epsTrailing":-1.04,"epsForward":0,"revenuePerShare":1.53,"bookValue":4.28,"officers":[{"age":48,"name":"Mr. Charles N. York II, M.B.A.","title":"COO & CFO"},{"age":58,"name":"Mr. Adam  Dubow J.D.","title":"General Counsel"}],"industry":"Biotechnology","irWebsite":"","website":"https://dayonebio.com","phone":"650 484 0899"}}